SCHEMBL17508474

SCHEMBL17508474

Fc1ccc(Oc2cccc3ccncc23)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.53
HTT P42858 2/20 0.53
LMNA P02545 2/20 0.53
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49
TNF P01375 2/20 0.42
CACNA2D1 P54289 4/20 0.41
KMT2A Q03164 2/20 0.41
ATM Q13315 1/20 0.41
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
TRPA1 O75762 2/20 0.40
MEN1 O00255 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9272721 0.87 TNF (0.53) MAPTHTTLMNATNFSIRT2
SCHEMBL17508472 0.77 HPGD (0.47) MAPTKMT2ACYP1A2CYP2C9CYP2C19
SCHEMBL9858637 0.76 CCNC (0.63) MAPTHTTLMNACA12CA1
SCHEMBL17508466 0.75 MAPT (0.58) MAPTHTTLMNACA12CA1
SCHEMBL7226299 0.74 SIRT2 (0.50) MAPTHTTLMNAKMT2ATRPA1
SCHEMBL23544069 0.74 TNF (0.49) MAPTLMNATNFCACNA2D1CYP1A2
SCHEMBL1491286 0.74 MAPT (0.56) MAPTLMNATNFCACNA2D1
SCHEMBL8322359 0.73 KCNA3 (0.66) MAPTHTTLMNATNFCYP1A2
SCHEMBL9858440 0.73 LMNA (0.52) MAPTHTTLMNACA12CA1
SCHEMBL14340747 0.73 KCNA3 (0.50) MAPTHTTLMNACACNA2D1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016021742-A1 HETEROCYCLIC COMPOUNDS AS EP4 RECEPTOR ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-02-11 WO disclosed
WO-2016021742-A1 HETEROCYCLIC COMPOUNDS AS EP4 RECEPTOR ANTAGONISTS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-02-11 WO disclosed